Skip to content

Study · Not a test of the peptide alone · 1983

4 results

Plasma norepinephrine and epinephrine responses to glucagon in patients with suspected pheochromocytomas.

Levinson PD, Hamilton BP, Mersey JH, Kowarski AA

Metabolism: clinical and experimental1 Oct 1983Cited by 9 (Europe PMC)

PMID6888268 (opens in a new tab)DOI10.1016/0026-0495(83)90142-7 (opens in a new tab)PepBankPUB-06888268
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Glucagon.

  1. 01HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In patients with suspected pheochromocytoma, the norepinephrine response to glucagon predicted tumor presence or absence in 27 of 28 patients.

    In plain wordsIn patients with suspected pheochromocytoma, the norepinephrine response to glucagon predicted tumor presence or absence in 27 of 28 patients.

    Peptide
    Glucagon
    Outcome
    Not applicableNorepinephrine diagnostic response
    Study

    n = 28

    Outcome group
    Diagnostic test performance · Endocrine and hormones

    Measurements

    Correct predictions
    27 patients
    28 tested

    Source sentences

    Summary
    The norepinephrine response predicted the presence or absence of a tumor in 27 of the 28 patients.
    1 context sentence
    Summary · context
    Plasma norepinephrine and epinephrine levels were measured before and after glucagon administration in 28 patients suspected of having a pheochromocytoma: three patients were subsequently found to have tumors.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  2. 02HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In patients with suspected pheochromocytoma, epinephrine levels after glucagon did not distinguish patients with tumors from those without tumors.

    In plain wordsIn patients with suspected pheochromocytoma, epinephrine levels after glucagon did not distinguish those with tumors from those without tumors.

    Peptide
    Glucagon
    Outcome
    Not applicableEpinephrine diagnostic discrimination
    Study

    n = 28

    Comparator
    Patients with versus without pheochromocytoma
    Outcome group
    Diagnostic test performance · Endocrine and hormones

    Source sentences

    Summary
    Epinephrine levels doubled, on the average, in patients who did not have pheochromocytomas, and were not useful in distinguishing the patients with or without tumors.
    1 context sentence
    Summary · context
    Plasma norepinephrine and epinephrine levels were measured before and after glucagon administration in 28 patients suspected of having a pheochromocytoma: three patients were subsequently found to have tumors.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  3. 03HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In patients without pheochromocytoma, epinephrine levels doubled on average after glucagon.

    In plain wordsIn patients without pheochromocytoma, epinephrine levels doubled on average after glucagon compared with before administration.

    Peptide
    Glucagon
    Outcome
    IncreaseEpinephrine response in patients without pheochromocytoma
    Study

    n: not reported in source

    Comparator
    Before glucagon
    Outcome group
    Diagnostic test performance · Endocrine and hormones

    Source sentences

    Summary
    Epinephrine levels doubled, on the average, in patients who did not have pheochromocytomas, and were not useful in distinguishing the patients with or without tumors.
    1 context sentence
    Summary · context
    Plasma norepinephrine and epinephrine levels were measured before and after glucagon administration in 28 patients suspected of having a pheochromocytoma: three patients were subsequently found to have tumors.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  4. 04HumanNot a test of Glucagon aloneNon-randomized trialMechanism

    In patients with suspected pheochromocytoma, comparison with placebo attributed catecholamine changes to glucagon rather than injection side effects.

    In plain wordsIn patients with suspected pheochromocytoma, placebo comparison linked catecholamine changes to glucagon rather than injection side effects.

    Peptide
    Glucagon
    Outcome
    Direction not reportedCatecholamine response versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    A comparison of the response to glucagon and a placebo indicated that changes in plasma catecholamine levels were hormone-related and not the result of side-effects accompanying injection.
    1 context sentence
    Summary · context
    Plasma norepinephrine and epinephrine levels were measured before and after glucagon administration in 28 patients suspected of having a pheochromocytoma: three patients were subsequently found to have tumors.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.